Showing 1501-1510 of 1676 results for "".
- SIFI Appoints Jelle Kleijn to Lead Effort to Deliver First Registered Treatment of Acanthamoeba Keratitishttps://modernod.com/news/sifi-appoints-jelle-kleijn-to-lead-effort-to-deliver-first-registered-treatment-of-acanthamoeba-keratitis/2478631/SIFI has announced the recent appointment of Jelle Kleijn, PhD, as Global Head of Acanthamoeba keratitis. Dr. Kleijn will lead the efforts aimed at developing and making polihexanide monotherapy available to Acanthamoeba keratitis (AK) patients. Given the urgency to effectively treat AK to
- Nicox Announces Senior Management Changehttps://modernod.com/news/nicox-announces-senior-management-change/2478295/Nicox announced that Tomas Navratil, PhD, Executive Vice President & Head of Research & Development of the Nicox Group and General Manager of Nicox Ophthalmics, will be leaving the company on October 16, 2020 to pursue other opportunities. Nicox has initiated a search for a successor. In
- NIH Selects Dr. Michael Chiang as Director of the National Eye Institutehttps://modernod.com/news/nih-selects-dr-michael-chiang-as-director-of-the-national-eye-institute/2478074/National Institutes of Health Director Francis S. Collins, MD, PhD, has chosen Michael F. Chiang, MD, as director of NIH’s National Eye Institute (NEI). A practicing ophthalmologist, Dr. Chiang is currently the Knowles Professor of Ophthalmology & Medical Informatics and Clinical Epide
- Tarsus Pharmaceuticals Announces Appointment of New COO and CFOhttps://modernod.com/news/tarsus-pharmaceuticals-announces-appointment-of-new-coo-and-cfo/2478029/Tarsus Pharmaceuticals announced the appointment of two pharmaceutical veterans to its executive leadership team: Sesha Neervannan, PhD, to the position of Chief Operating Officer (COO), and Leo Greenstein to the position of Chief Financial Officer (CFO). As part of its leadership, Sesha and Leo
- NYU Langone Names New Chair of Ophthalmologyhttps://modernod.com/news/nyu-langone-names-new-chair-of-ophthalmology/2477903/Kathryn A. Colby, MD, PhD, an internationally renowned physician–scientist, has been appointed chair of the Department of Ophthalmology at NYU Langone Health. She assumes her new post this fall. Dr. Colby is currently the Louis Block Professor and chair of the Department of Ophthalmology a
- Can You Catch COVID-19 Through Your Eyes?https://modernod.com/news/can-you-catch-covid-19-through-your-eyes/2477840/You can catch COVID-19 if an infected person coughs or sneezes and contagious droplets enter your nose or mouth. But can you become ill if the virus lands in your eyes? Virologist Joseph Fair, PhD, an NBC News contributor, raised that concern when he became critically ill with COVID-19, ac
- Nicox to Present NCX 470 Phase 2 Results at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/nicox-to-present-ncx-470-phase-2-results-at-glaucoma-360-new-horizons-forum/2477281/Nicox SA today announced that Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group, and General Manager of Nicox Ophthalmics, Inc, will present results from the NCX 470 Dolomites phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 N
- ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatmenthttps://modernod.com/news/forwardvue-pharma-ceo-short-path-to-the-clinic-for-retinal-disease-treatment/2477263/In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.
- Watching for Radiation Harm After Interventional Procedureshttps://modernod.com/news/watching-for-radiation-harm-after-interventional-procedures/2477165/Interventional procedures can expose interventionalists and nearby staff to high doses of radiation, and this can lead to radiation-associated lens opacities, said Madan Rehani, PhD, director of Global Outreach for Radiation Protection at Massachusetts General Hospital in Boston, in a Medscape
- Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officerhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-david-a-hollander-md-mba-as-chief-research-development-officer/2477056/Aerie Pharmaceuticals announced the appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., PhD, Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on Nov